Global Humanized Monoclonal Antibody Drugs Supply, Demand and Key Producers, 2025-2031
Page: 143
Published Date: 19 Jun 2025
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Humanized Monoclonal Antibody Drugs market size is expected to reach $ 263525 million by 2031, rising at a market growth of 10.1% CAGR during the forecast period (2025-2031).
Humanized monoclonal antibody drugs are therapeutic antibodies that are predominantly derived from human antibody structures, but with small portions—typically the complementarity-determining regions (CDRs)—originating from non-human species, such as mice. These drugs are engineered through recombinant DNA technology to reduce immunogenicity while maintaining high specificity and binding affinity to the target antigen. Humanized antibodies are widely used to treat cancers, autoimmune diseases, and inflammatory conditions.
This report studies the global Humanized Monoclonal Antibody Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Humanized Monoclonal Antibody Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2024 as the base year. This report explores demand trends and competition, as well as details the characteristics of Humanized Monoclonal Antibody Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Humanized Monoclonal Antibody Drugs total market, 2020-2031, (USD Million)
Global Humanized Monoclonal Antibody Drugs total market by region & country, CAGR, 2020-2031, (USD Million)
U.S. VS China: Humanized Monoclonal Antibody Drugs total market, key domestic companies, and share, (USD Million)
Global Humanized Monoclonal Antibody Drugs revenue by player, revenue and market share 2020-2025, (USD Million)
Global Humanized Monoclonal Antibody Drugs total market by Type, CAGR, 2020-2031, (USD Million)
Global Humanized Monoclonal Antibody Drugs total market by Application, CAGR, 2020-2031, (USD Million)
This report profiles major players in the global Humanized Monoclonal Antibody Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co, AbbVie, Eli Lilly & Co, Roche, Takeda, GlaxoSmithKline, UCB, AstraZeneca, Biogen, Gilead Sciences, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Humanized Monoclonal Antibody Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2020-2031 by year with 2024 as the base year, 2025 as the estimate year, and 2026-2031 as the forecast year.
Global Humanized Monoclonal Antibody Drugs Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Humanized Monoclonal Antibody Drugs Market, Segmentation by Type
Pembrolizumab
Risenqizumab
Orelizumab
Ixekizumab
Vedolizumab
Bevacizumab
Omalizumab
Farisimab
Trastuzumab
Other
Global Humanized Monoclonal Antibody Drugs Market, Segmentation by Application:
Cancers
Autoimmune Diseases
Inflammatory Condition
Companies Profiled:
Merck & Co
AbbVie
Eli Lilly & Co
Roche
Takeda
GlaxoSmithKline
UCB
AstraZeneca
Biogen
Gilead Sciences
Novartis
Teva
Qilu Pharma
Sun Pharmaceutical
Johnson & Johnson
Beigene
Pfizer
Innovent Bio
Key Questions Answered
1. How big is the global Humanized Monoclonal Antibody Drugs market?
2. What is the demand of the global Humanized Monoclonal Antibody Drugs market?
3. What is the year over year growth of the global Humanized Monoclonal Antibody Drugs market?
4. What is the total value of the global Humanized Monoclonal Antibody Drugs market?
5. Who are the Major Players in the global Humanized Monoclonal Antibody Drugs market?
6. What are the growth factors driving the market demand?
Table of Contents
1 Supply Summary
1.1 Humanized Monoclonal Antibody Drugs Introduction
1.2 World Humanized Monoclonal Antibody Drugs Market Size & Forecast (2020 & 2024 & 2031)
1.3 World Humanized Monoclonal Antibody Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Humanized Monoclonal Antibody Drugs Market Size by Region (2020-2031), (by Headquarter Location)
1.3.2 United States Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.3.3 China Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.3.4 Europe Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.3.5 Japan Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.3.6 South Korea Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.3.7 ASEAN Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.3.8 India Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031)
1.4 Market Drivers, Restraints and Trends
1.4.1 Humanized Monoclonal Antibody Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2.1 World Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.2 World Humanized Monoclonal Antibody Drugs Consumption Value by Region
2.2.1 World Humanized Monoclonal Antibody Drugs Consumption Value by Region (2020-2025)
2.2.2 World Humanized Monoclonal Antibody Drugs Consumption Value Forecast by Region (2026-2031)
2.3 United States Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.4 China Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.5 Europe Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.6 Japan Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.7 South Korea Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.8 ASEAN Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
2.9 India Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031)
3.1 World Humanized Monoclonal Antibody Drugs Revenue by Player (2020-2025)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Humanized Monoclonal Antibody Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Humanized Monoclonal Antibody Drugs in 2024
3.2.3 Global Concentration Ratios (CR8) for Humanized Monoclonal Antibody Drugs in 2024
3.3 Humanized Monoclonal Antibody Drugs Company Evaluation Quadrant
3.4 Humanized Monoclonal Antibody Drugs Market: Overall Company Footprint Analysis
3.4.1 Humanized Monoclonal Antibody Drugs Market: Region Footprint
3.4.2 Humanized Monoclonal Antibody Drugs Market: Company Product Type Footprint
3.4.3 Humanized Monoclonal Antibody Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4.1 United States VS China: Humanized Monoclonal Antibody Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Humanized Monoclonal Antibody Drugs Revenue Comparison (2020 & 2024 & 2031) (by Headquarter Location)
4.1.2 United States VS China: Humanized Monoclonal Antibody Drugs Revenue Market Share Comparison (2020 & 2024 & 2031)
4.2 United States Based Companies VS China Based Companies: Humanized Monoclonal Antibody Drugs Consumption Value Comparison
4.2.1 United States VS China: Humanized Monoclonal Antibody Drugs Consumption Value Comparison (2020 & 2024 & 2031)
4.2.2 United States VS China: Humanized Monoclonal Antibody Drugs Consumption Value Market Share Comparison (2020 & 2024 & 2031)
4.3 United States Based Humanized Monoclonal Antibody Drugs Companies and Market Share, 2020-2025
4.3.1 United States Based Humanized Monoclonal Antibody Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Humanized Monoclonal Antibody Drugs Revenue, (2020-2025)
4.4 China Based Companies Humanized Monoclonal Antibody Drugs Revenue and Market Share, 2020-2025
4.4.1 China Based Humanized Monoclonal Antibody Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Humanized Monoclonal Antibody Drugs Revenue, (2020-2025)
4.5 Rest of World Based Humanized Monoclonal Antibody Drugs Companies and Market Share, 2020-2025
4.5.1 Rest of World Based Humanized Monoclonal Antibody Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Humanized Monoclonal Antibody Drugs Revenue (2020-2025)
5.1 World Humanized Monoclonal Antibody Drugs Market Size Overview by Type: 2020 VS 2024 VS 2031
5.2 Segment Introduction by Type
5.2.1 Pembrolizumab
5.2.2 Risenqizumab
5.2.3 Orelizumab
5.2.4 Ixekizumab
5.2.5 Vedolizumab
5.2.6 Bevacizumab
5.2.7 Omalizumab
5.2.8 Farisimab
5.2.9 Trastuzumab
5.3 Market Segment by Type
5.3.1 World Humanized Monoclonal Antibody Drugs Market Size by Type (2020-2025)
5.3.2 World Humanized Monoclonal Antibody Drugs Market Size by Type (2026-2031)
5.3.3 World Humanized Monoclonal Antibody Drugs Market Size Market Share by Type (2026-2031)
6.1 World Humanized Monoclonal Antibody Drugs Market Size Overview by Application: 2020 VS 2024 VS 2031
6.2 Segment Introduction by Application
6.2.1 Cancers
6.2.2 Autoimmune Diseases
6.2.3 Inflammatory Condition
6.3 Market Segment by Application
6.3.1 World Humanized Monoclonal Antibody Drugs Market Size by Application (2020-2025)
6.3.2 World Humanized Monoclonal Antibody Drugs Market Size by Application (2026-2031)
6.3.3 World Humanized Monoclonal Antibody Drugs Market Size Market Share by Application (2020-2031)
7.1 Merck & Co
7.1.1 Merck & Co Details
7.1.2 Merck & Co Major Business
7.1.3 Merck & Co Humanized Monoclonal Antibody Drugs Product and Services
7.1.4 Merck & Co Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.1.5 Merck & Co Recent Developments/Updates
7.1.6 Merck & Co Competitive Strengths & Weaknesses
7.2 AbbVie
7.2.1 AbbVie Details
7.2.2 AbbVie Major Business
7.2.3 AbbVie Humanized Monoclonal Antibody Drugs Product and Services
7.2.4 AbbVie Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.2.5 AbbVie Recent Developments/Updates
7.2.6 AbbVie Competitive Strengths & Weaknesses
7.3 Eli Lilly & Co
7.3.1 Eli Lilly & Co Details
7.3.2 Eli Lilly & Co Major Business
7.3.3 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product and Services
7.3.4 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.3.5 Eli Lilly & Co Recent Developments/Updates
7.3.6 Eli Lilly & Co Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche Humanized Monoclonal Antibody Drugs Product and Services
7.4.4 Roche Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 Takeda
7.5.1 Takeda Details
7.5.2 Takeda Major Business
7.5.3 Takeda Humanized Monoclonal Antibody Drugs Product and Services
7.5.4 Takeda Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.5.5 Takeda Recent Developments/Updates
7.5.6 Takeda Competitive Strengths & Weaknesses
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Details
7.6.2 GlaxoSmithKline Major Business
7.6.3 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product and Services
7.6.4 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.6.5 GlaxoSmithKline Recent Developments/Updates
7.6.6 GlaxoSmithKline Competitive Strengths & Weaknesses
7.7 UCB
7.7.1 UCB Details
7.7.2 UCB Major Business
7.7.3 UCB Humanized Monoclonal Antibody Drugs Product and Services
7.7.4 UCB Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.7.5 UCB Recent Developments/Updates
7.7.6 UCB Competitive Strengths & Weaknesses
7.8 AstraZeneca
7.8.1 AstraZeneca Details
7.8.2 AstraZeneca Major Business
7.8.3 AstraZeneca Humanized Monoclonal Antibody Drugs Product and Services
7.8.4 AstraZeneca Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.8.5 AstraZeneca Recent Developments/Updates
7.8.6 AstraZeneca Competitive Strengths & Weaknesses
7.9 Biogen
7.9.1 Biogen Details
7.9.2 Biogen Major Business
7.9.3 Biogen Humanized Monoclonal Antibody Drugs Product and Services
7.9.4 Biogen Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.9.5 Biogen Recent Developments/Updates
7.9.6 Biogen Competitive Strengths & Weaknesses
7.10 Gilead Sciences
7.10.1 Gilead Sciences Details
7.10.2 Gilead Sciences Major Business
7.10.3 Gilead Sciences Humanized Monoclonal Antibody Drugs Product and Services
7.10.4 Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.10.5 Gilead Sciences Recent Developments/Updates
7.10.6 Gilead Sciences Competitive Strengths & Weaknesses
7.11 Novartis
7.11.1 Novartis Details
7.11.2 Novartis Major Business
7.11.3 Novartis Humanized Monoclonal Antibody Drugs Product and Services
7.11.4 Novartis Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.11.5 Novartis Recent Developments/Updates
7.11.6 Novartis Competitive Strengths & Weaknesses
7.12 Teva
7.12.1 Teva Details
7.12.2 Teva Major Business
7.12.3 Teva Humanized Monoclonal Antibody Drugs Product and Services
7.12.4 Teva Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.12.5 Teva Recent Developments/Updates
7.12.6 Teva Competitive Strengths & Weaknesses
7.13 Qilu Pharma
7.13.1 Qilu Pharma Details
7.13.2 Qilu Pharma Major Business
7.13.3 Qilu Pharma Humanized Monoclonal Antibody Drugs Product and Services
7.13.4 Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.13.5 Qilu Pharma Recent Developments/Updates
7.13.6 Qilu Pharma Competitive Strengths & Weaknesses
7.14 Sun Pharmaceutical
7.14.1 Sun Pharmaceutical Details
7.14.2 Sun Pharmaceutical Major Business
7.14.3 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product and Services
7.14.4 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.14.5 Sun Pharmaceutical Recent Developments/Updates
7.14.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
7.15 Johnson & Johnson
7.15.1 Johnson & Johnson Details
7.15.2 Johnson & Johnson Major Business
7.15.3 Johnson & Johnson Humanized Monoclonal Antibody Drugs Product and Services
7.15.4 Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.15.5 Johnson & Johnson Recent Developments/Updates
7.15.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.16 Beigene
7.16.1 Beigene Details
7.16.2 Beigene Major Business
7.16.3 Beigene Humanized Monoclonal Antibody Drugs Product and Services
7.16.4 Beigene Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.16.5 Beigene Recent Developments/Updates
7.16.6 Beigene Competitive Strengths & Weaknesses
7.17 Pfizer
7.17.1 Pfizer Details
7.17.2 Pfizer Major Business
7.17.3 Pfizer Humanized Monoclonal Antibody Drugs Product and Services
7.17.4 Pfizer Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.17.5 Pfizer Recent Developments/Updates
7.17.6 Pfizer Competitive Strengths & Weaknesses
7.18 Innovent Bio
7.18.1 Innovent Bio Details
7.18.2 Innovent Bio Major Business
7.18.3 Innovent Bio Humanized Monoclonal Antibody Drugs Product and Services
7.18.4 Innovent Bio Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025)
7.18.5 Innovent Bio Recent Developments/Updates
7.18.6 Innovent Bio Competitive Strengths & Weaknesses
8.1 Humanized Monoclonal Antibody Drugs Industry Chain
8.2 Humanized Monoclonal Antibody Drugs Upstream Analysis
8.3 Humanized Monoclonal Antibody Drugs Midstream Analysis
8.4 Humanized Monoclonal Antibody Drugs Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Humanized Monoclonal Antibody Drugs Revenue by Region (2020, 2024 and 2031) & (USD Million), (by Headquarter Location)
Table 2. World Humanized Monoclonal Antibody Drugs Revenue by Region (2020-2025) & (USD Million), (by Headquarter Location)
Table 3. World Humanized Monoclonal Antibody Drugs Revenue by Region (2026-2031) & (USD Million), (by Headquarter Location)
Table 4. World Humanized Monoclonal Antibody Drugs Revenue Market Share by Region (2020-2025), (by Headquarter Location)
Table 5. World Humanized Monoclonal Antibody Drugs Revenue Market Share by Region (2026-2031), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Humanized Monoclonal Antibody Drugs Consumption Value Growth Rate Forecast by Region (2020 & 2024 & 2031) & (USD Million)
Table 8. World Humanized Monoclonal Antibody Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 9. World Humanized Monoclonal Antibody Drugs Consumption Value Forecast by Region (2026-2031) & (USD Million)
Table 10. World Humanized Monoclonal Antibody Drugs Revenue by Player (2020-2025) & (USD Million)
Table 11. Revenue Market Share of Key Humanized Monoclonal Antibody Drugs Players in 2024
Table 12. World Humanized Monoclonal Antibody Drugs Industry Rank of Major Player, Based on Revenue in 2024
Table 13. Global Humanized Monoclonal Antibody Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Humanized Monoclonal Antibody Drugs Players
Table 15. Humanized Monoclonal Antibody Drugs Market: Company Product Type Footprint
Table 16. Humanized Monoclonal Antibody Drugs Market: Company Product Application Footprint
Table 17. Humanized Monoclonal Antibody Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Humanized Monoclonal Antibody Drugs Revenue Comparison, (2020 & 2024 & 2031) & (USD Million)
Table 19. United States VS China Humanized Monoclonal Antibody Drugs Consumption Value Comparison, (2020 & 2024 & 2031) & (USD Million)
Table 20. United States Based Humanized Monoclonal Antibody Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Humanized Monoclonal Antibody Drugs Revenue, (2020-2025) & (USD Million)
Table 22. United States Based Companies Humanized Monoclonal Antibody Drugs Revenue Market Share (2020-2025)
Table 23. China Based Humanized Monoclonal Antibody Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Humanized Monoclonal Antibody Drugs Revenue, (2020-2025) & (USD Million)
Table 25. China Based Companies Humanized Monoclonal Antibody Drugs Revenue Market Share (2020-2025)
Table 26. Rest of World Based Humanized Monoclonal Antibody Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Humanized Monoclonal Antibody Drugs Revenue (2020-2025) & (USD Million)
Table 28. Rest of World Based Companies Humanized Monoclonal Antibody Drugs Revenue Market Share (2020-2025)
Table 29. World Humanized Monoclonal Antibody Drugs Market Size by Type, (USD Million), 2020 & 2024 & 2031
Table 30. World Humanized Monoclonal Antibody Drugs Market Size Value by Type (2020-2025) & (USD Million)
Table 31. World Humanized Monoclonal Antibody Drugs Market Size by Type (2026-2031) & (USD Million)
Table 32. World Humanized Monoclonal Antibody Drugs Market Size by Application, (USD Million), 2020 & 2024 & 2031
Table 33. World Humanized Monoclonal Antibody Drugs Market Size by Application (2020-2025) & (USD Million)
Table 34. World Humanized Monoclonal Antibody Drugs Market Size by Application (2026-2031) & (USD Million)
Table 35. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 36. Merck & Co Major Business
Table 37. Merck & Co Humanized Monoclonal Antibody Drugs Product and Services
Table 38. Merck & Co Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 39. Merck & Co Recent Developments/Updates
Table 40. Merck & Co Competitive Strengths & Weaknesses
Table 41. AbbVie Basic Information, Manufacturing Base and Competitors
Table 42. AbbVie Major Business
Table 43. AbbVie Humanized Monoclonal Antibody Drugs Product and Services
Table 44. AbbVie Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 45. AbbVie Recent Developments/Updates
Table 46. AbbVie Competitive Strengths & Weaknesses
Table 47. Eli Lilly & Co Basic Information, Manufacturing Base and Competitors
Table 48. Eli Lilly & Co Major Business
Table 49. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product and Services
Table 50. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 51. Eli Lilly & Co Recent Developments/Updates
Table 52. Eli Lilly & Co Competitive Strengths & Weaknesses
Table 53. Roche Basic Information, Manufacturing Base and Competitors
Table 54. Roche Major Business
Table 55. Roche Humanized Monoclonal Antibody Drugs Product and Services
Table 56. Roche Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 57. Roche Recent Developments/Updates
Table 58. Roche Competitive Strengths & Weaknesses
Table 59. Takeda Basic Information, Manufacturing Base and Competitors
Table 60. Takeda Major Business
Table 61. Takeda Humanized Monoclonal Antibody Drugs Product and Services
Table 62. Takeda Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 63. Takeda Recent Developments/Updates
Table 64. Takeda Competitive Strengths & Weaknesses
Table 65. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 66. GlaxoSmithKline Major Business
Table 67. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product and Services
Table 68. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 69. GlaxoSmithKline Recent Developments/Updates
Table 70. GlaxoSmithKline Competitive Strengths & Weaknesses
Table 71. UCB Basic Information, Manufacturing Base and Competitors
Table 72. UCB Major Business
Table 73. UCB Humanized Monoclonal Antibody Drugs Product and Services
Table 74. UCB Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 75. UCB Recent Developments/Updates
Table 76. UCB Competitive Strengths & Weaknesses
Table 77. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 78. AstraZeneca Major Business
Table 79. AstraZeneca Humanized Monoclonal Antibody Drugs Product and Services
Table 80. AstraZeneca Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 81. AstraZeneca Recent Developments/Updates
Table 82. AstraZeneca Competitive Strengths & Weaknesses
Table 83. Biogen Basic Information, Manufacturing Base and Competitors
Table 84. Biogen Major Business
Table 85. Biogen Humanized Monoclonal Antibody Drugs Product and Services
Table 86. Biogen Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 87. Biogen Recent Developments/Updates
Table 88. Biogen Competitive Strengths & Weaknesses
Table 89. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 90. Gilead Sciences Major Business
Table 91. Gilead Sciences Humanized Monoclonal Antibody Drugs Product and Services
Table 92. Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 93. Gilead Sciences Recent Developments/Updates
Table 94. Gilead Sciences Competitive Strengths & Weaknesses
Table 95. Novartis Basic Information, Manufacturing Base and Competitors
Table 96. Novartis Major Business
Table 97. Novartis Humanized Monoclonal Antibody Drugs Product and Services
Table 98. Novartis Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 99. Novartis Recent Developments/Updates
Table 100. Novartis Competitive Strengths & Weaknesses
Table 101. Teva Basic Information, Manufacturing Base and Competitors
Table 102. Teva Major Business
Table 103. Teva Humanized Monoclonal Antibody Drugs Product and Services
Table 104. Teva Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 105. Teva Recent Developments/Updates
Table 106. Teva Competitive Strengths & Weaknesses
Table 107. Qilu Pharma Basic Information, Manufacturing Base and Competitors
Table 108. Qilu Pharma Major Business
Table 109. Qilu Pharma Humanized Monoclonal Antibody Drugs Product and Services
Table 110. Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 111. Qilu Pharma Recent Developments/Updates
Table 112. Qilu Pharma Competitive Strengths & Weaknesses
Table 113. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 114. Sun Pharmaceutical Major Business
Table 115. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product and Services
Table 116. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 117. Sun Pharmaceutical Recent Developments/Updates
Table 118. Sun Pharmaceutical Competitive Strengths & Weaknesses
Table 119. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 120. Johnson & Johnson Major Business
Table 121. Johnson & Johnson Humanized Monoclonal Antibody Drugs Product and Services
Table 122. Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 123. Johnson & Johnson Recent Developments/Updates
Table 124. Johnson & Johnson Competitive Strengths & Weaknesses
Table 125. Beigene Basic Information, Manufacturing Base and Competitors
Table 126. Beigene Major Business
Table 127. Beigene Humanized Monoclonal Antibody Drugs Product and Services
Table 128. Beigene Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 129. Beigene Recent Developments/Updates
Table 130. Beigene Competitive Strengths & Weaknesses
Table 131. Pfizer Basic Information, Manufacturing Base and Competitors
Table 132. Pfizer Major Business
Table 133. Pfizer Humanized Monoclonal Antibody Drugs Product and Services
Table 134. Pfizer Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 135. Pfizer Recent Developments/Updates
Table 136. Pfizer Competitive Strengths & Weaknesses
Table 137. Innovent Bio Basic Information, Manufacturing Base and Competitors
Table 138. Innovent Bio Major Business
Table 139. Innovent Bio Humanized Monoclonal Antibody Drugs Product and Services
Table 140. Innovent Bio Humanized Monoclonal Antibody Drugs Revenue, Gross Margin and Market Share (2020-2025) & (USD Million)
Table 141. Innovent Bio Recent Developments/Updates
Table 142. Innovent Bio Competitive Strengths & Weaknesses
Table 143. Global Key Players of Humanized Monoclonal Antibody Drugs Upstream (Raw Materials)
Table 144. Global Humanized Monoclonal Antibody Drugs Typical Customers
List of Figures
Figure 1. Humanized Monoclonal Antibody Drugs Picture
Figure 2. World Humanized Monoclonal Antibody Drugs Total Revenue: 2020 & 2024 & 2031, (USD Million)
Figure 3. World Humanized Monoclonal Antibody Drugs Total Revenue (2020-2031) & (USD Million)
Figure 4. World Humanized Monoclonal Antibody Drugs Revenue by Region (2020, 2024 and 2031) & (USD Million), (by Headquarter Location)
Figure 5. World Humanized Monoclonal Antibody Drugs Revenue Market Share by Region (2020-2031), (by Headquarter Location)
Figure 6. United States Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 7. China Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 8. Europe Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 9. Japan Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 10. South Korea Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 11. ASEAN Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 12. India Based Company Humanized Monoclonal Antibody Drugs Revenue (2020-2031) & (USD Million)
Figure 13. Humanized Monoclonal Antibody Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 16. World Humanized Monoclonal Antibody Drugs Consumption Value Market Share by Region (2020-2031)
Figure 17. United States Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 18. China Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 19. Europe Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 20. Japan Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 21. South Korea Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 22. ASEAN Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 23. India Humanized Monoclonal Antibody Drugs Consumption Value (2020-2031) & (USD Million)
Figure 24. Producer Shipments of Humanized Monoclonal Antibody Drugs by Player Revenue ($MM) and Market Share (%): 2024
Figure 25. Global Four-firm Concentration Ratios (CR4) for Humanized Monoclonal Antibody Drugs Markets in 2024
Figure 26. Global Four-firm Concentration Ratios (CR8) for Humanized Monoclonal Antibody Drugs Markets in 2024
Figure 27. United States VS China: Humanized Monoclonal Antibody Drugs Revenue Market Share Comparison (2020 & 2024 & 2031)
Figure 28. United States VS China: Humanized Monoclonal Antibody Drugs Consumption Value Market Share Comparison (2020 & 2024 & 2031)
Figure 29. World Humanized Monoclonal Antibody Drugs Market Size by Type, (USD Million), 2020 & 2024 & 2031
Figure 30. World Humanized Monoclonal Antibody Drugs Market Size Market Share by Type in 2024
Figure 31. Pembrolizumab
Figure 32. Risenqizumab
Figure 33. Orelizumab
Figure 34. Ixekizumab
Figure 35. Vedolizumab
Figure 36. Bevacizumab
Figure 37. Omalizumab
Figure 38. Farisimab
Figure 39. Omalizumab
Figure 40. World Humanized Monoclonal Antibody Drugs Market Size Market Share by Type (2020-2031)
Figure 41. World Humanized Monoclonal Antibody Drugs Market Size by Application, (USD Million), 2020 & 2024 & 2031
Figure 42. World Humanized Monoclonal Antibody Drugs Market Size Market Share by Application in 2024
Figure 43. Cancers
Figure 44. Autoimmune Diseases
Figure 45. Inflammatory Condition
Figure 46. World Humanized Monoclonal Antibody Drugs Market Size Market Share by Application (2020-2031)
Figure 47. Humanized Monoclonal Antibody Drugs Industrial Chain
Figure 48. Methodology
Figure 49. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Merck & Co AbbVie Eli Lilly & Co Roche Takeda GlaxoSmithKline UCB AstraZeneca Biogen Gilead Sciences Novartis Teva Qilu Pharma Sun Pharmaceutical Johnson & Johnson Beigene Pfizer Innovent Bio
19 Jun 2025
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
